Female Genital System Neoplasms

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2017-03-27
Clinical Trial Update: Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies [Phase 1]
This Phase 1 trial of alisertib in combination with TAK-228 for HPV-associated malignancies has been withdrawn.